Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, William G. Wierda et al.|The Lancet|2021Cited by 456
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, John M. Pagel et al.|Blood|2020Cited by 26
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, John M. Pagel et al.|Blood|2021Cited by 15
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N. Shah, Jennifer R. Brown, Michael Wang et al.|Haematologica|2024Cited by 12
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A. Yap, Lu Gan, Randy F. Sweis et al.|Nature Medicine|2026Cited by 2